

## SATURDAY 20 FEBRUARY

08.00 AM Registration, welcome coffee

08.30 AM Opening of the Workshop

### Session 1 Prevention in Women

**Chairs:** Catherine Hankins, Kathleen Squires

08.45 AM **Biomedical Prevention in Women**

**Nelly Mugo, MBChB, MPH**, Kenya Medical Research Institute, Kenya

09.15 AM **Prevention in young women**

**Sinéad Delany - Moretlwe, MBBCH, PhD**, Wits RHI, South Africa

09.45 AM **Female condom, diaphragms, cervical caps and other barrier methods**

**Jill Schwartz, MD, MPH**, CONRAD, USA

10.15 AM **Discussion**

10.30 AM Coffee break

### Round Table Discussion: What are the next steps in Prevention?

**Chairs:** Catherine Hankins, Kathleen Squires


11.00 AM **Invited lecture: Long-acting antiretroviral prevention (injectables, rings, etc.)**

**Sharon Hillier, PhD**, University of Pittsburgh School of Medicine, USA

11.30 AM **Panel discussion**

### 12.00 PM Guided poster tour

|         |                                                                                                                                                                 |              |       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| Theme 1 | <i>Effect of Doravirine (MK-1439) on the pharmacokinetics of an oral contraceptive (Ethinyl Estradiol [EE] and Levonorgestrel [LNG])</i>                        | M. Anderson  | PP_19 |
|         | <i>Effective contraceptive use, dual contraception, and contraceptive method choice among women living with HIV in Canada</i>                                   | A. Kaida     | PP_20 |
|         | <i>Reaching women in serodifferent relationships: safer conception and contraceptive counseling by providers of men living with HIV</i>                         | D. Seidman   | PP_21 |
|         | <i>Pregnancy outcomes for women using regimens including darunavir or other protease inhibitors: Findings from the Antiretroviral Pregnancy Registry</i>        | W. Short     | PP_22 |
|         | <i>Use of antiretroviral regimens including darunavir during pregnancy: Findings from the Antiretroviral Pregnancy Registry</i>                                 | W. Short     | PP_23 |
| Theme 2 | <i>Coercive sex as a mode of HIV acquisition among a cohort of women with HIV in Canada: an under-recognized public health concern</i>                          | M. Loutfy    | PP_24 |
|         | <i>This might be the only place for those kinds of needs": a qualitative study of U.S. family planning providers' attitudes towards PrEP for HIV prevention</i> | A. Rodriguez | PP_25 |
|         | <i>Bacterial vaginosis and HIV RNA vaginal shedding in women living with HIV in Denmark - Results from the SHADE Cohort</i>                                     | M. Wessman   | PP_26 |



*Navigational Spatial Memory Test (MI) as a Cognitive Marker for HIV-associated Neurocognitive Disorder*

R. Rodriguez- Benitez PP\_27

01.00 PM Lunch

## Session 2 Women living with HIV

**Chairs:** Natella Rakhmanina, Patricia Vasquez & Mona Loutfy

02.00 PM **Transgender women \_ research issues**

**Javier Lama, MD, MPH**, IMPACTA Peru, Peru

02.30 PM **Transgender women \_ real life experience**

*Speaker to be confirmed*

### Abstract - driven presentations

03.00 PM Exploring contexts of HIV vulnerability and protective factors among young transgender women in Kingston, Jamaica

C. Logie O\_01

03.15 PM Social drivers of HIV vulnerability among lesbian, bisexual, queer and transgender women in Swaziland

C. Logie O\_02

03.30 PM **Discussion**

04.00 PM **Coffee Break and Poster Viewing Session 1 (P-28 to P-83)**

## Session 3 Abstract driven presentation (Prevention related)

**Chairs:**

### Abstract - driven presentations

04.30 PM Comparison of Adherence Measures in a Phase 1 Clinical Trial of PC-1005 Vaginal Gel

L. Katzen O\_03

04.45 PM MIP-3a is detectable constitutively in female genital tract tissues; however, endogenous hormonal fluctuations do not impact on its levels

S. Sibeko O\_04

05.00 PM Reduced activation of emtricitabine and tenofovir in cervical and vaginal explants from post-menopausal donors

M. Nicol O\_05

05.15 PM Use of HIV pre-exposure prophylaxis during conception, pregnancy and lactation at 2 U.S. medical centers

D. Seidman O\_06


05.30 PM Use of injectable hormonal contraception independently predicts HSV-2 acquisition in a cohort of street- and off-street sex workers in Vancouver, Canada

M. E. Socias O\_07

05.45 PM Strategies to improve the uptake of effective contraception in HIV-positive adolescents

N. Kancheva Landolt O\_08

06.00 PM **Drinks & Poster viewing session 2 (P-39 to P-49)**



## SUNDAY 21 FEBRUARY

### Session 4 Treatment - Current ARV in women

**Chairs:** Margaret Johnson, Sharon Walmsley & Annette Sohn

08.30 AM **When to start // When not to start**

**Anna Maria Geretti, MD, PhD**, University of Liverpool, Institute of Infection & Global Health, UK

09.00 AM **Current treatment of HIV in pregnancy**

**Annemiek de Ruiter, FRCP**, Guy's and St Thomas' Hospital, UK

#### Abstract - driven presentations

09.30 AM Does delivery after 40 weeks gestation increase maternal to child transmission of HIV in well controlled HIV-infected pregnant women? A prospective cohort study R. Scott O\_09

09.45 AM PK of FTC, TFF and 3TC in Ugandan and Nigerian breastfeeding mother-infant pairs S. Nakalema O\_10

10.00 AM **Round table discussion**

10.30 AM Coffee Break

### Session 5 Abstract driven presentations (Treatment-related)

#### Abstract - driven presentations

11.00 AM Treatments and co-morbidities in German female HIV-infected patients in 2015 - a comparison to 2008 N. Hanhoff O\_11

11.15 AM Patient characteristics, duration on antiretrovirals (ARVs) and adherence in an insured US population receiving ARVs in 2010-2014: a focus on women J. Forlenza O\_12


11.30 AM mHealth to improve health: a weekly text messaging intervention to improve ART adherence and HIV viral load in a Canadian context: WelTel OAKTREE A. Qiu O\_13

11.45 AM The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines I. Boucoiran O\_14

12.00 AM Viral suppression and retention in care 2-5 years after ART initiation in pregnancy in Uganda C. Koss O\_15

**12.15 PM Group Picture**

12.30 PM Lunch



## Session 6 Treatment - Continuum of care

**Chairs:** Margaret Johnson, Sharon Walmsley & Annette Sohn

01.30 PM **Socio-economic status and HIV treatment outcomes among women**

**Fiona Lampe, PhD**, University College London, UK

02.00 PM **Option B+**

**Landon Myer, MD, PhD**, University of Cape Town, South Africa

### Abstract - driven presentations

02.30 PM Factors influencing Lost to Follow-up in a Prevention of Mother-To-Child Transmission (PMTCT) Program in Northern Nigeria F. Oluwasina O\_16

02.35 PM Retention overtime and reasons for discontinuation of lifelong ART in a group of Cameroonian pregnant and breastfeeding HIV-positive women initiating "Option B+" P. Atanga O\_17

02.40 PM **Discussion**

03.00 PM Coffee Break

## Session 7 Co-infection issues

**Chairs:** Cindy Firnhaber

03.30 PM **Young women of child bearing age presenting with MDR TB**

**Francesca Conradie, MD**, University of the Witwatersrand, South Africa

04.00 PM **Co-infection with hepatitis C in women**

**Arthur Kim, MD**, Massachusetts General Hospital, USA

### Abstract - driven presentation

04.30 PM The Hepatitis C cascade of care in a women-centered HIV clinic in Canada A. Mah O\_18

04.40 PM **Discussion**

05.00 PM Closure